Digoxin: Na⁺/K⁺ ATPase Pump Inhibitor for Cardiac and Antiviral Research

Executive Summary: Digoxin is a cardiac glycoside that inhibits the Na⁺/K⁺-ATPase pump, thereby enhancing cardiac contractility in preclinical models (APExBIO, product page). The compound is validated for arrhythmia, heart failure, and antiviral research, with dose-dependent inhibition of chikungunya virus infection in U-2 OS, primary human synovial fibroblasts, and Vero cells at 0.01–10 μM (Saul et al., DOI). Digoxin is soluble at ≥33.25 mg/mL in DMSO, but not in water or ethanol. Its efficacy and pharmacokinetics in animal models are well-documented, and APExBIO provides high-purity (>98.6%) Digoxin with QC data for reproducible research. The product supports rigorous cardiac and virology workflows in both cellular and animal studies.

Biological Rationale

Cardiac glycosides such as Digoxin are crucial in the study of cardiovascular diseases, particularly heart failure and arrhythmias. Digoxin modulates cardiac contractility by increasing intracellular calcium via Na⁺/K⁺-ATPase inhibition, a mechanism exploited in translational models of congestive heart failure (CHF) and arrhythmic syndromes (see related). Its antiviral properties, notably against chikungunya virus (CHIKV), position it as a dual-purpose tool for studying host-pathogen interactions and cardiac electrophysiology. Unlike some other cardiac glycosides, Digoxin has robust, reproducible benchmarks in both cell-based and animal models of disease, facilitating cross-laboratory comparability. This article extends coverage from prior reviews by providing updated benchmarks, solubility parameters, and validated workflows for APExBIO's Digoxin SKU B7684, emphasizing both mechanistic rigor and translational readiness.

Mechanism of Action of Digoxin

Digoxin exerts its primary effect by binding to and inhibiting the Na⁺/K⁺-ATPase pump, a membrane protein critical for maintaining cellular ionic gradients. Inhibition of this pump increases intracellular sodium, which in turn reduces the activity of the sodium-calcium exchanger, leading to elevated intracellular calcium concentrations. The resulting calcium accumulation enhances contractility of cardiac myocytes, an effect termed positive inotropy (mechanistic details). In addition to its cardiac effects, Na⁺/K⁺-ATPase inhibition disrupts viral replication cycles, as demonstrated in multiple CHIKV-infected human cell lines exposed to Digoxin. The dual pathway modulation—cardiac and antiviral—makes Digoxin a unique probe for dissecting Na⁺/K⁺-ATPase signaling in cardiovascular and infectious disease research.

Evidence & Benchmarks

• Digoxin increases cardiac output and reduces right atrial pressure in canine models of congestive heart failure following intravenous administration (1–1.2 mg) (Saul et al., DOI).
• Digoxin exhibits dose-dependent inhibition of chikungunya virus infection in U-2 OS, primary human synovial fibroblasts, and Vero cells at concentrations of 0.01–10 μM (Saul et al., DOI).
• The compound is highly soluble in DMSO (≥33.25 mg/mL), but insoluble in water and ethanol (APExBIO, product datasheet).
• APExBIO’s Digoxin (SKU B7684) is provided at >98.6% purity, with quality control including HPLC, NMR, and MSDS documentation (product QC).
• Long-term storage of Digoxin solutions is not recommended; solutions should be prepared fresh and used promptly for reproducible results (see workflow guidance).

Applications, Limits & Misconceptions

Digoxin’s primary research uses include investigating cardiac contractility, arrhythmias, heart failure, and the inhibition of chikungunya virus infection. The compound is validated in preclinical animal models (canine, murine) and multiple human cell lines. Its utility as a Na⁺/K⁺-ATPase signaling probe extends to studies on ion transport, signal transduction, and host-pathogen interactions. Compared to other cardiac glycosides, Digoxin is favored for its robust, dose-responsive activity and well-characterized pharmacokinetics (see comparative discussion—this article updates with new benchmarks and QC parameters).

Common Pitfalls or Misconceptions

• Digoxin is not effective in water-based systems without a suitable solvent, as it is insoluble in water and ethanol (use DMSO at ≥33.25 mg/mL).
• It does not reverse acute viral infections in vivo; its antiviral activity is documented in cell-based assays, not clinical endpoints.
• Long-term storage of reconstituted Digoxin solutions leads to loss of potency; always prepare fresh before use.
• Digoxin does not substitute for antiarrhythmic drugs in acute arrhythmia models; its mechanism is primarily inotropy modulation, not rhythm correction.
• Its efficacy in non-mammalian models or plant systems remains unverified.

Workflow Integration & Parameters

For in vitro applications, Digoxin should be dissolved in DMSO at concentrations up to 33.25 mg/mL. Recommended working concentrations for antiviral assays are 0.01–10 μM, with controls for cell viability and DMSO vehicle effects. In animal studies, intravenous administration in canine heart failure models ranges from 1–1.2 mg per subject, with cardiac output and right atrial pressure as primary endpoints (DOI). APExBIO supplies Digoxin as a solid with full QC documentation (HPLC, NMR, MSDS) and recommends room temperature storage. For reproducibility, all solutions should be freshly prepared, and experimental details (temperature, buffer, animal strain, cell line) should be recorded. For extended guidance on troubleshooting and workflow optimization, see our in-depth workflow article (this review synthesizes recent pharmacokinetic and QC updates).

Conclusion & Outlook

Digoxin remains an essential Na⁺/K⁺-ATPase pump inhibitor for research into cardiac contractility, heart failure, arrhythmias, and antiviral mechanisms. Its high purity, validated benchmarks, and robust documentation—supplied by APExBIO—make it a gold standard for translational workflows. With reproducible results across cell-based and animal models, Digoxin (SKU B7684) facilitates innovation at the interface of cardiovascular and infectious disease research. Future directions include expanded mechanistic studies and integration with omics platforms to further dissect Na⁺/K⁺-ATPase-mediated signaling in health and disease.